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ABSTRACT
Colorectal carcinogenesis is a multi-factorial process which involves accumulation of genetic defect, protein 
modi cation, and cell interaction with matrix in colonic epithelial cells. Chronic in ammation is suspected to play 
role in carcinogenesis by inhibiting apoptosis, impairing DNA, and chronically stimulating mucosal proliferation. 
Alteration in intestinal microbes’ population, either in one particular species or in overall composition, may 
also cause chronic in ammation which increase the risk of developing adenoma or carcinoma.
 In ammatory mediators and intestinal microbes have diverse effect in colorectal carcinogenesis. Several may 
increase host anti-tumor immunity, while the others may increase tumor growth. Various ways of interactions 
have just started to be partially understood. In addition, colorectal cancer chemoprevention is a promising and 
important knowledge due to limited success of current available therapy. Chemopreventive agents are currently 
being studied and have different success rate.
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ABSTRAK
Karsinogenesis kolorektal adalah proses multifaktorial yang melibatkan akumulasi dari defek genetik, 
modi kasi protein dan interaksi sel dengan matriks pada sel epitel kolon. In amasi kronik diduga berperan 
pada karsinogenesis dengan menghambat apoptosis, merusak DNA, dan menstimulasi proliferasi mukosa secara 
kronik. Perubahan pada populasi mikroba usus, baik pada spesies tertentu ataupun pada komposisinya secara 
keseluruhan, mungkin juga dapat menyebabkan in amasi kronik yang meningkatkan risiko perkembangan 
menjadi adenoma dan karsinoma. 
Mediator in amasi dan mikrobiota usus memiliki efek yang beragam pada karsinogenesis kolorektal. Beberapa 
dapat meningkatkan imunitas anti-tumor pejamu, sementara lainnya dapat meningkatkan pertumbuhan tumor. 
Berbagai cara proses tersebut berinteraksi baru dipahami sebagian. Kemoprevensi kanker kolorektal merupakan 
ilmu yang menjanjikan dan penting dikarenakan terbatasnya keberhasilan terapi. Agen kemopreventif kanker 
saat ini masih banyak diteliti dan memiliki tingkat keberhasilan yang berbeda-beda.
Kata kunci: in amasi, mikrobiota, kemoprevensi, karsinogenesis, kanker kolorektal
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INTRODUCTION
In United States, incidence of colorectal cancer 
(CRC) is 160,000 cases, from which 57,000 die of the 
disease every year. This incidence decreased as much 
as 3% between 1998-2005, as efforts in screening and 
surveillance were increased, however CRC is now 
still the second leading cause of death from cancer 
among adults.1 Indonesian Study Group of Colorectal 
Adenocarcinoma stated that the incidence of CRC in 
Indonesia was 1.8 per 100,000 population.2 CRC starts 
from a benign adenomatous polyp, which develops 
into advance adenoma with high level of dysplasia and 
further develops into invasive adenocarcinoma.3 This is 
a multi-factorial process through complex interaction 
between genetic and environmental factors.4 Chronic 
in ammation condition, depending on the duration 
and severity of in ammation, is often associated with 
increased risk of developing malignancy. Chronic 
in ammation is suspected to play role in carcinogenesis 
by inhibiting apoptosis, impairing DNA, and chronically 
stimulating mucosal proliferation. This chronic 
in ammation condition is often found in patients with 
in ammatory bowel disease (IBD), or in patients with 
particular bacterial infection.5,6 
CRC is a serious problem which accompanies IBD 
patients and causes 10-15% death in IBD patients.7 
Crohn and Rosenberg have recognized the increase risk 
of CRC in ulcerative colitis (UC) patients since 1925. 
Cumulative risk for CRC after 20 years diagnosis of 
UC varies between 1-34%.5,8-10 This variation is caused 
by age difference at diagnosis, sex, extend and duration 
of disease, and the availability of referral hospital. 
A meta-analysis predicts CRC risk in UC patients is 
increased, as much as 2% after 10 years, 8% after 20 
years, and 18% after 30 years being diagnosed with 
UC.11 Similarly, Crohn Disease (CD) increases the risk 
for CRC as much as 2.9% after 10 years, 5.6% after 20 
years, and 8.3% after 30 years from the initial onset of 
the disease.12 The risk of CRC increases in line with 
the duration of the disease and the extent of colorectal 
involvement. Latest study has also supported the 
severity of microscopic in ammation as a risk factor.13 
Patients with UC and CD are at an increased risk of 
developing CRC through variety mechanism which 
has not been fully understood. 
This review article will discuss on chronic 
in ammation aspect; several in ammatory mediators 
and intestinal microbes, which influence the 
development of CRC. Also, it will discuss on the 
potential target which can give opportunity to the 
development of therapeutic intervention and even 
chemoprevention, which could be proved to be 
effective in inhibiting the progression of colitis-
associated cancer (CAC).
ROLE OF INFLAMMATORY MEDIATORS IN 
COLORECTAL CARCINOGENESIS
Oxidative Stress
Tumor protein 53-induced nuclear protein 1 
(TP53INP1) is an antiproliferative and proapoptotic 
protein which is involved in cell response to stress. A 
study demonstrated that oxidative stress, which was 
increased in TP53INP1-de cient mice, produced more 
severe colitis and supported its development to CRC.14
A group of researcher reported an increased 
incidence of adenocarcinoma in the colon in UC 
animal model without administration of carcinogenic 
substances. They succeed in inducing neoplasia in 
mice which did not have 8-oxoguanine glycosylase 
(Ogg1) enzyme.15 This study revealed that Ogg1 was 
an important enzyme to repair DNA in colitis and 
probably play a signi cant role in preventing dysplastic 
changes in the in amed epithelium. Interestingly, 
this researcher group also reported CRC inhibition 
by inositol compounds might be associated with its 
function on the modulation of macrophage-mediated 
in ammation and oxidative stress.16 Generally, this 
 nding showed that oxidative stress response in the 
in amed gut might contribute in the promotion and 
progression of CRC.5
Cyclooxygenase-2 (COX-2)
Two isoforms of cyclooxygenase (COX) enzyme 
are COX-1 dan COX-2. COX-1 is expressed in normal 
tissue and plays important role in tissue homeostasis, 
while COX-2 is an inducible enzyme, which is 
expressed abundantly in the location of in ammation 
and colorectal neoplasm. COX-2 catalyzes the 
synthesis of prostaglandins (PGs) from arachidonic 
acid. COX-2 expression is activated by a number 
of proin ammatory cytokines, including interleukin 
(IL)-1 α, IL-1 β, and tumor necrosis factor-α (TNF-α).5 
COX-2 is induced in colonic epithelium of patients 
with active IBD and in in amed tissues of IL-10-
de cient mice. COX-2 is expressed very early in the 
pathogenesis of CRC. In its association with human 
cancer, COX-2 is over-expressed in about 80% CRC 
and 40% colorectal adenoma when compared with 
normal mucosa.17 
Many evidences have showed that the pro-
in ammatory and tumor-promoting effects of COX-2 
31
Chronic Inflammation in Colorectal Carcinogenesis: Role of Inflammatory Mediators, Intestinal Microbes, and Chemoprevention Potency
are mediated by prostaglandin E2 (PGE2). COX-2 
increases enterocyte proliferation, positively regulates 
angiogenesis, and stimulates cell migration and 
invasion through PGE2 molecule. PGE2 may directly 
regulate colon carcinogenesis by regulating Wingless 
and INT (WNT) signaling pathway, which has a crucial 
role in colon carcinogenesis.5 
Tumor Necrosis Factor-α (TNF-α)
TNF-α is a cytokine member of TNF and is a 
key molecule which control in ammation and host 
defense. Activation of TNF p55 dan p75 receptor 
causes intracellular proteins recruitment, which 
later activate several particular signal transduction 
pathways, such as: nuclear factor-κB (NF-κB).18 TNF-α 
involves in DNA damage through the formation of 
reactive oxygen species. However, antioxidants may 
signi cantly reduce TNF-α-induced genetic damage in 
these cells.19 TNF-α treatment in cultured cell causes 
increasing of gene mutation, gene amplification, 
micronuclei formation and chromosomal instability. 
Furthermore, TNF-Rp55 gene ablation and TNF 
antagonist administration reduces COX-2 expression 
and tumor angiogenesis in colitis-associated cancer 
(CAC) animal models.20 Therefore, TNF-α may also 
increase tumor angiogenesis by inducing the in ltration 
of COX-2 expressing macrophages and neutrophils. 
Combination of these results shows that inhibition of 
TNF-α may diminish progression of colon carcinoma 
by reducing COX-2 expression and also indirectly 
inhibiting the WNT signaling pathway.5
This cytokine levels are increased in the blood 
and colonic mucosa of UC and CD patients. The use 
of anti-TNF-α antibodies, which has been proven to 
be effective in IBD, is the most recent development. 
However, the implications to human’s CRC are 
unknown yet.5 This is interesting to be waited for, 
whether this anticytokine therapy will in uence CRC 
development in IBD patients.
Nuclear Factor-κB (NF-κB)
Nuclear factor-κB (NF-κB) has been considered to 
be important in the process between in ammation and 
carcinogenesis. NF-κB is a transcription factor which 
has function to increase proliferation and survival. 
TNF-α and other pro-in ammatory cytokines, which 
are: interleukin (IL)-1, toll-like receptors (TLR) can 
activate NF-κB signaling pathway.5 Activation of 
NF-κB is needed for the expression of a range of 
proin ammatory molecules, including cytokines and 
adhesion molecules.21 Results of study performed by 
Greten et al. explained that signal for survival, which 
was produced by NF-κB, played important role in the 
initiation of CRC.22
Sulfasalazine and methotrexate are widely used in 
acute phase of IBD treatment, by inhibiting NF-κB 
activity. Other agents, such as: curcumin and ginseng 
extract, may also inhibit NF-κB activity.23-25
Interleukin-6 (IL-6)
Recent studies stressed on the role of IL-6 in the 
development of IBD and its progression to CRC.5 
Mouse model have shown that IL-6 stimulate survival, 
proliferation, and progression to cancer from intestinal 
epithelial cells. Furthermore, level of IL-6 is increased 
in the serum of colon cancer patients, and can be 
induced by TNF-α.5 Latest study in human showed 
that patients with active UC, dysplasia and cancer 
had signi cantly higher level of IL-6 compared with 
inactive UC patients and control.26 Becker et al, also 
succeed to demonstrate that inhibition of IL-6 with 
antibody to IL-6 might decrease tumor size.27
Interleukin-10 (IL-10)
IL-10 has anti-in ammatory activities.5 Mice whose 
IL-10 activity was eliminated might experience severe 
intestinal in ammation due to intestinal normal  ora, 
which further developed into colitis and CRC.28
ROLE OF INFECTION IN  COLORECTAL 
CARCINOGENESIS
Lately, knowledge about microbes as one of 
malignancy causes due to chronic in ammation is 
developing. As an example, Helicobacter pylori (H. 
pylori) in gastric cancer and human papilloma virus 
(HPV) in cervical cancer.6
In normal colon, microbes maintain colonic mucosa 
in physiologic mild inflammation condition, and 
stimulate the release of pro-in ammatory cytokines. 
Alteration in colon microbes has signi cant effect in 
the development of colon neoplasia, possibly through 
the production of heterocyclic aromatic amino acid and 
superoxide components. Some studies have shown the 
presence of several microbes which can increase this 
process, while some other microbes may overcome 
this destructive effect. Currently, it was suspected that 
changes in intestinal microbes population, either in 
particular species or in overall composition, may cause 
chronic in ammation which then increase the risk of 
developing adenoma or carcinoma.29
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Some microbes which have been studied are:30
• Lactobacillus salivarius
 Studies in mice showed that Lactobacillus salivarius 
might reduce the intensity of in ammation in 
intestinal mucosa, reduce the incidence of colon 
cancer from 50% to 10%, and reduce the population 
of enterococcus and Clostridium perfringens. 
• Streptococcus bovis
 Association between colon malignancies with 
endocarditis due to Streptococcus bovis (S. bovis) 
was  rst reported in a case report in 1951. S. bovis 
was thought as a risk factor of colorectal neoplasia, 
possibly induce oncogenesis through host immune 
response. Currently, screening colonoscopy is 
recommended for all patients who have history of 
bacteremia or endocarditis due to S. bovis. 
• Helicobacter pylori
 The association of Helicobacter pylori (H. pylori) 
with colorectal cancer has not been widely known. 
Hypergastrinemia, which is related to H. pylori 
colonization, is suspected as a mechanism which 
causes colorectal carcinogenesis. Hypergastrinemia 
has trophy effect in intestinal mucosa.
• Escherichia coli
 Escherichia coli (E. coli) is a normal  ora in 
human digestive tract; however the species which 
is attached to the mucosa can possibly cause 
neoplasia. Several studies showed that E. coli 
which is present in mucosa or intraepithelial, is 
often found in colon mucosa of patients with colon 
adenocarcinoma, but not found in normal control. 
This mechanism may be caused by intimin protein 
which is produced by enteropathogenic E. coli. 
This protein may decrease the DNA repair process 
in vitro, thus increase the possibility of colon 
epithelial cells to develop into malignant tumor. 
• Clostridium septicum
 Clostridium septicum (C. septicum) has been 
correlated to several hematologic malignancies, 
particularly leukemia. However, some case reports 
also reported the association between C. septicum 
infection and colorectal cancer, particularly in diabetic 
patients. There is no evidence that C. septicum has 
effect in colorectal tumorigenesis. It was suspected 
that disturbed intestinal mucosa in CRC is the port 
de entry of this organism to the blood stream. 
• Enterococcus faecalis
 Enterococcus faecalis is part of human intestinal 
microbes which produce oxygen free radicals, 
including extracellular superoxide, which can 
impair colonic epithelial cells DNA, either in vitro 
or in vivo. However, there is no study which reveals 
the association of intestinal colonization by this 
bacteria and colorectal cancer development. 
Some types of virus, such as: human papiloma virus 
(HPV), John Cunningham virus (JCV), Epstein-Barr 
virus (EBV), cytomegalovirus (CMV), also has been 
studied for their association with CRC incidence and 
still showed inconclusive results.29
COLORECTAL CANCER CHEMOPREVENTION 
POTENCY
Early screening of CRC is the most important and 
as a key for management in most patients. In addition, 
CRC chemoprevention is a promising and important 
knowledge, as there is still limited success of current 
available therapy. Nowadays, cancer chemopreventive 
agents have diverse success rate. 
COX-2 Inhibitor
COX-2 inhibitor has been known to suppress 
sporadic CRC, however it is still unknown whether 
COX-2 inhibitor also has preventive effect to colitis 
associated CRC. Non-steroid anti-in ammation drugs 
(NSAIDs) “sulindac” is an effective chemopreventive 
agent in sporadic CRC; yet the bene t potency in colitis 
associated CRC is still need to be investigated.30-32 
COX-2 inhibitor has been found to induce apoptosis 
in tumor cells and to inhibit tumor growth in animal 
models and in humans.5 Mukawa et al explored the 
effect of etodolac, a selective COX-2 inhibitor, to 
tumorigenesis in CAC model of p53-de cient mice 
which received DSS. It was found that etodolac could 
decrease the occurrence of neoplasia signi cantly.33 
Etodolac might also decrease the occurrence of 
aberrant crypt foci and tumors in rats.34 PC-407 
(4-[5-naphthyl-3-(tri uoromethyl)-1H-pyrazol-1-yl] 
benzenesulfonamide), a celecoxib derivates, was 
found to downregulate COX-2 mRNA, protein level 
and PGE2 production signi cantly in conjunction with 
tumor growth inhibition.35
5-aminosalicylic Acid
Chemopreventive ability of 5-aminosalicylic 
acid (5-ASA) can be associated with 5 different 
pathways, which are: interference with cell cycle 
progression, scavenging of reactive oxygen- or 
nitrogen derived metabolites, TNF-α signaling, 
WNT/β-catenin signaling, and antibacterial activity.5 
Study in animal support the role of 5-ASA in 
inhibiting CRC development in mice during or 
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after the induction of inflammation. 5-ASA is 
only effective if administered during and/or after 
intestinal in ammation. Interestingly, 5-ASA decrease 
proliferation of epithelial cells in colitis associated 
CRC but not in sporadic CRC.36 Results from several 
observational study supported the protective role 
between 5-ASA and colitis associated CRC. Study by 
Eaden et al, revealed that mesalamine was effective 
in decreasing cancer risk as much as 81% and that 
mesalamine had greater protective effect compared to 
sulfasalazine.37,38 However, latest clinical study in long 
term UC patients failed to show the preventive role of 
mesalamine in progression of  at low-grade dysplasia 
to advance neoplasia.39
Folic Acid
Folate maintains the normal DNA methylation 
process and steady-state condition of DNA precursors. 
This role indicate that folate has potential as 
chemopreventive agent.5 Recent study suggests that 
in IBD patients with normal homocysteine level, the 
increase in carcinogenic risk is negligible. Different 
with patients with hyper-homocysteinemia, folate 
de ciency may be associated with increased risk of 
colitis associated CRC.40 Depressed red blood cell 
folate is related to increased risk of dysplasia and 
cancer in UC patients and may play role as a risk factor 
for neoplastic transformation. Case control studies 
have shown that folate may be protective against 
CAC. Lashner et al, examined the effect of folate 
supplementation in 98 UC patients (minimal for 8 
years of duration) and exhibited dose-response effect, 
also supported the role of folate in CRC prevention.41 
Therefore, daily folate supplementation may protect 
against CRC development in UC patients.
Ursodeoxycholic Acid
Ursodeoxycholic acid (UDCA) has shown 
effectiveness as colon cancer chemopreventive agents 
in variety pre-clinical studies.5 Deoxycholic acid 
(DCA) has been linked with colonic carcinogenesis 
through effect mediated by protein kinase C activation. 
UDCA inhibits DCA-induced translocation of 
protein kinase C. This mechanism make UDCA has 
chemopreventive effect to colon carcinogenesis.42 
UDCA administration in mouse model of colitis 
decrease the expression of TNF-α in colonic mucosa.43 
Pardi et al, evaluated the effect of UDCA in colorectal 
neoplasia in a group of UC patients and obtained result 
that UDCA signi cantly decreased the risk to develop 
colorectal dysplasia or CRC in that population.44
CONCLUSION
In ammatory mediators and intestinal microbes have 
diverse effect in colorectal carcinogenesis. Interleukin-10 
may increase host antitumor immunity, while the others: 
COX-2, TNF-α, NF-κB, and interleukin-6, may increase 
development of CRC. L. salivarius may decrease CRC 
incidence, while S. bovis, and H. pylori were suspected 
as risk factors of CRC. As an addition, 5-ASA, folic acid, 
and ursodeoxycholic acid are CRC chemopreventive 
agents, which are promising and important, as there 
is still limited success with current available therapy. 
Further studies on genetic, epigenetic, and immunologic 
mechanism which modulate a range of in ammatory 
mediators and intestinal microbes which play role 
in the progression from physiologic into pathologic 
in ammation and CRC neoplasia are still needed.
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